Day: April 23, 2026

BUDZ Highlights Valuable Legacy Genetics Portfolio Following Historic Federal Schedule III Marijuana Action WEED Inc. (OTCQB:BUDZ) Positioned with Rare Landrace Strains as DOJ Announces Immediate Schedule III Pathway for Qualified Medical Marijuana Products

TailorMed Expands its Solutions Suite to Address Barriers Across the Medication Journey, Building on its Market-Leading Affordability Solution and Growing its National Network

Expanded capabilities help patients and partners navigate access, affordability, and adherence across the healthcare ecosystem NEW YORK CITY, NY /...

Medical Care Technologies Inc. (OTC PINK:MDCE) Accelerates Growth Strategy with Strategic Capital Raise Following Launch of AI Consumer Platform

MESA, AZ / ACCESS Newswire / April 23, 2026 / Medical Care Technologies Inc. (OTC PINK:MDCE) today announced a strategic...

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)

- IDE supplement expands trial to the other primary standard-of-care chemotherapy for pancreatic cancer patients, alongside mFOLFIRINOX - - IDE...

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial

ACAPELLA is the European multicenter clinical trial evaluating Alpha DaRT alpha-emitter radiotherapeutics combined with capecitabine for inoperable LAPC patients who...

H1 Launches Site Network Suite, the First AI-Powered Platform to Transform How Research Sites and Sponsors Engage on Clinical Trials

H1’s Core AI Engine Helps Sponsors Find Sites More Efficiently and Determine Feasibility Faster, Bringing Process from Months to WeeksNEW...

Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M

- PRIDCor Therapeutics Granted Global Development and Commercialization License for IMC-1 and IMC-2 Assets for All Indications, including Fibromyalgia and...

Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis

Expect to report topline data from both studies mid-2026SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited...

error: Content is protected !!